Completed PHASE3 INTERVENTIONAL NCT00211094

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

A Placebo-Controlled, Double-blind, Randomized, Parallel Study of the Efficacy and Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation

Sponsor: Alza Corporation, DE, USA

Conditions Ejaculation

Interventions Dapoxetine

Updated 5 times since 2017 Last updated: Feb 10, 2011 Completion: Jun 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00211094, this PHASE3 trial focuses on Ejaculation and remains completed. Sponsored by Alza Corporation, DE, USA, it has been updated 5 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alza Corporation, DE, USA

Data source: Alza Corporation, DE, USA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.